Financial reports
Current reports
6-K
Current report (foreign)
29 Mar 24
6-K
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
29 Mar 24
6-K
Current report (foreign)
9 Feb 24
6-K
Current report (foreign)
16 Jan 24
6-K
Adagene Presents Data Demonstrating the Best-in-Class Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 at SITC 2023
3 Nov 23
6-K
Current report (foreign)
29 Sep 23
6-K
Adagene Reports Six Month Financial Results for 2023 and Provides Corporate Update
31 Aug 23
6-K
Unleashing Anti - CTLA - 4 Therapy By Enhancing the Therapeutic Index July 2023
7 Jul 23
6-K
Current report (foreign)
4 May 23
6-K
Adagene Announces Updates to its Board of Directors
28 Apr 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
29 Mar 24
F-3/A
Shelf registration (foreign) (amended)
20 May 22
F-3/A
Shelf registration (foreign) (amended)
13 May 22
F-3
Shelf registration (foreign)
26 Apr 22
S-8
Registration of securities for employees
15 Apr 21
424B4
Prospectus supplement with pricing info
10 Feb 21
F-1/A
Registration statement (foreign) (amended)
5 Feb 21
8-A12B
Registration of securities on exchange
3 Feb 21
F-1/A
Registration statement (foreign) (amended)
3 Feb 21
F-1/A
Registration statement (foreign) (amended)
1 Feb 21
Proxies
No filings
Other
UPLOAD
Letter from SEC
11 Jul 23
CORRESP
Correspondence with SEC
10 Jul 23
CORRESP
Correspondence with SEC
16 Jun 23
UPLOAD
Letter from SEC
5 Jun 23
EFFECT
Notice of effectiveness
27 May 22
CORRESP
Correspondence with SEC
24 May 22
CORRESP
Correspondence with SEC
13 May 22
UPLOAD
Letter from SEC
6 May 22
EFFECT
Notice of effectiveness
9 Feb 21
EFFECT
Notice of effectiveness
9 Feb 21